193 related articles for article (PubMed ID: 34508564)
21. Anti-Mi-2 and Anti-TIF1-γ Double-Positive Juvenile Dermatomyositis Treated under Diagnosis of Chronic Eczema: A Case Report.
Yoshida S; Matsumoto H; Fujita Y; Yokose K; Temmoku J; Matsuoka N; Yashiro-Furuya M; Asano T; Sato S; Suzuki E; Yago T; Yaguchi T; Aita T; Kusano M; Yamamoto T; Watanabe H; Migita K
Tohoku J Exp Med; 2022 Apr; 256(4):303-308. PubMed ID: 35296571
[TBL] [Abstract][Full Text] [Related]
22. Antimelanoma Differentiation-associated Gene 5 Antibody: Expanding the Clinical Spectrum in North American Patients with Dermatomyositis.
Moghadam-Kia S; Oddis CV; Sato S; Kuwana M; Aggarwal R
J Rheumatol; 2017 Mar; 44(3):319-325. PubMed ID: 28089977
[TBL] [Abstract][Full Text] [Related]
23. Serum level of galectin-9 as a potential biomarker for high risk of malignancy in dermatomyositis.
Shih Y; Chen S; Huang J; Chen Y; Zhu Z; Zhao Q; Zhao X; Xue F; Xiang J; Chen X; Zhu X; Pan M; Wu J; Zheng J; Li H; Cao H
Rheumatology (Oxford); 2024 Jan; 63(1):251-258. PubMed ID: 37184873
[TBL] [Abstract][Full Text] [Related]
24. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
Fujisawa T; Hozumi H; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
J Rheumatol; 2019 Aug; 46(8):935-942. PubMed ID: 31092718
[TBL] [Abstract][Full Text] [Related]
25. Anti-Melanoma Differentiation-Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis.
Moghadam-Kia S; Oddis CV; Sato S; Kuwana M; Aggarwal R
Arthritis Care Res (Hoboken); 2016 May; 68(5):689-94. PubMed ID: 26414240
[TBL] [Abstract][Full Text] [Related]
26. Hierarchical cluster analysis of cytokine profiles reveals a cutaneous vasculitis-associated subgroup in dermatomyositis.
Bai J; Wu C; Zhong D; Xu D; Wang Q; Zeng X
Clin Rheumatol; 2021 Mar; 40(3):999-1008. PubMed ID: 32797361
[TBL] [Abstract][Full Text] [Related]
27. Anti-TIF1-γ autoantibodies: warning lights of a tumour autoantigen.
De Vooght J; Vulsteke JB; De Haes P; Bossuyt X; Lories R; De Langhe E
Rheumatology (Oxford); 2020 Mar; 59(3):469-477. PubMed ID: 31883334
[TBL] [Abstract][Full Text] [Related]
28. Endothelial and Inflammation Biomarker Profiles at Diagnosis Reflecting Clinical Heterogeneity and Serving as a Prognostic Tool for Treatment Response in Two Independent Cohorts of Patients With Juvenile Dermatomyositis.
Wienke J; Pachman LM; Morgan GA; Yeo JG; Amoruso MC; Hans V; Kamphuis SSM; Hoppenreijs EPAH; Armbrust W; van den Berg JM; Hissink Muller PCE; Gelderman KA; Arkachaisri T; van Wijk F; van Royen-Kerkhof A
Arthritis Rheumatol; 2020 Jul; 72(7):1214-1226. PubMed ID: 32103637
[TBL] [Abstract][Full Text] [Related]
29. Anti-TIF1-γ antibody and cancer-associated myositis: A clinicohistopathologic study.
Hida A; Yamashita T; Hosono Y; Inoue M; Kaida K; Kadoya M; Miwa Y; Yajima N; Maezawa R; Arai S; Kurasawa K; Ito K; Shimada H; Iwanami T; Sonoo M; Hatanaka Y; Murayama S; Uchibori A; Chiba A; Aizawa H; Momoo T; Nakae Y; Sakurai Y; Shiio Y; Hashida H; Yoshizawa T; Sakiyama Y; Oda A; Inoue K; Takeuchi S; Iwata NK; Date H; Masuda N; Mikata T; Motoyoshi Y; Uesaka Y; Maeda MH; Nakashima R; Tsuji S; Kwak S; Mimori T; Shimizu J
Neurology; 2016 Jul; 87(3):299-308. PubMed ID: 27343066
[TBL] [Abstract][Full Text] [Related]
30. Splicing factor proline/glutamine-rich is a novel autoantigen of dermatomyositis and associated with anti-melanoma differentiation-associated gene 5 antibody.
Hosono Y; Nakashima R; Serada S; Murakami K; Imura Y; Yoshifuji H; Ohmura K; Naka T; Mimori T
J Autoimmun; 2017 Feb; 77():116-122. PubMed ID: 27919567
[TBL] [Abstract][Full Text] [Related]
31. Two young-adult female cases of dermatomyositis with antibodies for transcriptional intermediary factor 1-γ.
Matsuura E; Ishiguro N; Katsumata Y; Urano W; Yamanaka H; Kondo M; Kuwana M; Kaji K; Hamaguchi Y; Fujimoto M; Kawashima M
Eur J Dermatol; 2012; 22(5):668-71. PubMed ID: 22992252
[TBL] [Abstract][Full Text] [Related]
32. HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody.
Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Watanabe K; Aihara K; Oga T; Chin K; Nagai S; Mimori T; Mishima M
Respir Med; 2011 Sep; 105(9):1380-7. PubMed ID: 21632230
[TBL] [Abstract][Full Text] [Related]
33. Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD.
Horiike Y; Suzuki Y; Fujisawa T; Yasui H; Karayama M; Hozumi H; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Ogawa N; Suda T
Rheumatology (Oxford); 2019 Dec; 58(12):2143-2152. PubMed ID: 31143953
[TBL] [Abstract][Full Text] [Related]
34. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease.
Sato S; Kuwana M; Fujita T; Suzuki Y
Mod Rheumatol; 2013 May; 23(3):496-502. PubMed ID: 22644102
[TBL] [Abstract][Full Text] [Related]
35. Paraneoplastic Dermatomyositis in a Patient with Metastatic Gastric Carcinoma.
Pozharashka J; Dourmishev L; Rusinova D; Balabanova M; Miteva L
Acta Dermatovenerol Croat; 2020 Aug; 28(2):120-122. PubMed ID: 32876041
[TBL] [Abstract][Full Text] [Related]
36. Clinical features and risk factors of lung cancer in elderly patients with dermatomyositis.
Zhou B; Li S; Xie X; Xu S; Li F; Long L
Thorac Cancer; 2023 May; 14(13):1171-1178. PubMed ID: 37042120
[TBL] [Abstract][Full Text] [Related]
37. Clinically amyopathic dermatomyositis: clinical features, response to medications and malignancy-associated risk factors in a specific tertiary-care-centre cohort.
Galimberti F; Li Y; Fernandez AP
Br J Dermatol; 2016 Jan; 174(1):158-64. PubMed ID: 26490490
[TBL] [Abstract][Full Text] [Related]
38. Genetic background may contribute to the latitude-dependent prevalence of dermatomyositis and anti-TIF1-γ autoantibodies in adult patients with myositis.
Parkes JE; Rothwell S; Oldroyd A; Chinoy H; Lamb JA;
Arthritis Res Ther; 2018 Jun; 20(1):117. PubMed ID: 29884237
[TBL] [Abstract][Full Text] [Related]
39. Clinical features of dermatomyositis patients with anti-TIF1 antibodies: A case based comprehensive review.
Kilinc OC; Ugurlu S
Autoimmun Rev; 2023 Dec; 22(12):103464. PubMed ID: 37863375
[TBL] [Abstract][Full Text] [Related]
40. Noninvasive positive pressure ventilator deteriorates the outcome of pneumomediastinum in anti-MDA5 antibody-positive clinically amyopathic dermatomyositis.
Zhou M; Ye Y; Yan N; Lian X; Bao C; Guo Q
Clin Rheumatol; 2020 Jun; 39(6):1919-1927. PubMed ID: 31942657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
